Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Trial of Adaptive 18F-FDG-PET Biological Intensity-modulated Radiotherapy (BG-IMRT) in Patients With Head and Neck Tumor

This study has been completed.
Information provided by:
University Hospital, Ghent Identifier:
First received: November 30, 2006
Last updated: September 3, 2010
Last verified: September 2010
This study will evaluate the feasibility of higher and prolonged dose escalation concentrated in the intra-tumoral regions which are FDG-avid after two weeks of radiotherapy.

Condition Intervention Phase
Head and Neck Tumor
Procedure: 18F-FDG-PET radiotherapy
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Trial of Adaptive 18F-FDG-PET Biological Intensity-modulated Radiotherapy (BG-IMRT) With Patients With Head and Neck Tumor

Resource links provided by NLM:

Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:
  • Tumor recurrences

Estimated Enrollment: 24
Study Start Date: November 2006
Study Completion Date: February 2010
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Head and neck tumor
  • Aged > 18 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00406289

University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
Principal Investigator: Wilfried De Neve, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
Responsible Party: Wilfried De Neve, University Hospital Ghent Identifier: NCT00406289     History of Changes
Other Study ID Numbers: 2006/391
Study First Received: November 30, 2006
Last Updated: September 3, 2010

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Fluorodeoxyglucose F18
Molecular Mechanisms of Pharmacological Action processed this record on May 22, 2017